-+ 0.00%
-+ 0.00%
-+ 0.00%

Reig Jofre 9M26 EBITDA falls 21% to EUR 19 million

PUBT·11/13/2026 07:20:31
Listen to the news
Reig Jofre 9M26 EBITDA falls 21% to EUR 19 million
  • Reig Jofre’s consolidated profit fell 47% year over year to EUR 1 million in the first nine months of 2026.
  • EBITDA dropped 21% to EUR 19 million, with the Forté Pharma fire weighing on performance.
  • Sales rose to EUR 242 million, with SPC growth offsetting the fire-related decline at Forté Pharma.
  • Biotechnology investments in Syna Therapeutics and Leanbio totaled EUR 13 million during the nine-month period.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Laboratorio Reig Jofre SA published the original content used to generate this news brief on November 13, 2026, and is solely responsible for the information contained therein.